Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
ERAS-0015 at 32 mg QD achieved 44% confirmed ORR in 2L+ KRAS G12X PDAC, despite heavy pretreatment (84% in the 3L+ setting) and a high proportion of G12R mutations (44% of patients) ERAS-0015 at 32 mg QD achieved 69% confirmed ORR in 2L+ KRAS G12D or G12V PDAC ERAS-0015 at 32 mg…